Clear All
399 Matching Results — Export these results
Click column titles once to sort ascending, and twice to sort descending.
HCPCS Generic Name Brand Name Strength SEER*Rx Category Major Drug Class Minor Drug Class Oral (Y/N) FDA Approval Year FDA Discontinuation Year CMS Effective Date CMS Discontinuation Date Status
NA Bromocriptine Mesylate Parlodel Chemotherapy Dopamine Agonist Ergot Derivative Yes 1978 In Use
J8510 Busulfan Myleran 2 mg Chemotherapy Alkylating Agent Alkylsulfonate Yes 1954 Jan 1, 2000 In Use
Repotrectinib Augtyro 40mg, 160mg Chemotherapy Tyrosine Kinase Inhibitor ROS1, TRKA, TRKB, TRKC Yes 2023 In Use
NA Vandetanib Caprelsa 300 mg Chemotherapy Tyrosine Kinase Inhibitor VEGFR, EGFR Yes 2011 In Use
Lazertinib Lazcluze 80mg, 240mg Chemotherapy Tyrosine Kinase Inhibitor EGFR Yes 2024 In Use
NA Panobinostat Farydak 10 mg Chemotherapy Enzyme Inhibitor HDAC Yes 2015 In Use
NA Regorafenib Stivarga 40 mg Chemotherapy Tyrosine Kinase Inhibitor VEGFR, FGF, PDGFR,KIT,RET,TIE2,DDR2,TrkQ,RAF,BRAF,SAPK2, PTK, Abl Yes 2012 In Use
NA Osimertinib Tagrisso 40 mg Chemotherapy Tyrosine Kinase Inhibitor EGFR Yes 2015 In Use
NA Nilotinib Tasigna 200 mg Chemotherapy Tyrosine Kinase Inhibitor BCR-ABL Yes 2007 In Use
NA Mitotane Lysodren unspecified Chemotherapy Miscellaneous Agent Adrenal Suppressant Yes 1970 In Use
J8561 Everolimus Afinitor, Afinitor Disperz 0.25 mg Chemotherapy Enzyme Inhibitor mTOR Yes 2009 Jan 1, 2012 Dec 31, 2012 No Longer Used
J8705 Topotecan Hycamtin 0.25 mg Chemotherapy Topoisomerase I Inhibitor Campothecin Analogs Yes 1996 Jan 1, 2009 In Use
NA Lapatinib Tykerb 250 mg Chemotherapy Tyrosine Kinase Inhibitor EGFR/HER2 Yes 2007 In Use
NA Ponatinib Iclusig 45 mg Chemotherapy Tyrosine Kinase Inhibitor BCR-ABL Yes 2012 In Use
NA Ponatinib Iclusig 15 mg Chemotherapy Tyrosine Kinase Inhibitor BCR-ABL Yes 2012 In Use
S0182 Procarbazine Matulane 50 mg Chemotherapy Alkylating Agent Benzamide Yes 1969 Jan 1, 2002 In Use
NA Enasidenib mesylate Idhifa 100 mg Chemotherapy Enzyme Inhibitor IDH2 Yes 2017 In Use
NA Rucaparib Rubraca 200 mg Chemotherapy Enzyme Inhibitor PARP Yes 2017 In Use
NA Encorafenib Braftovi 50mg, 75mg Chemotherapy BRAF Inhibitor V600E Yes 2018 In Use
NA Abemaciclib Verzenio 50 mg Chemotherapy Cyclin Dependent Kinase Inhibitor CDK 4/6 Yes 2017 In Use
NA Larotrectinib Vitrakvi 25mg, 100mg 20mg/ml Chemotherapy Tyrosine Kinase Inhibitor TRK Yes 2018 In Use
Niraparib and Abiraterone Akeega Multiple Chemotherapy Androgen Receptor Inhibitor, Enzyme Inhibitor CYP 17, PARP Yes 2023 In Use
NA Pemigatinib Pemazyre 4.5mg, 9mg, 13.5mg Chemotherapy Tyrosine Kinase Inhibitor FGFR1, FGFR2, FGFR3 Yes 2020 In Use
NA Ribociclib and letrozole Kisqali Femara Co-pack 200 mg/ 2.5 mg Chemotherapy, Hormonal Therapy Cyclin dependent kinase inhibitor/ aromatase inhibitor CDK 4/6 Yes 2017 In Use
NA Nilotinib Tasigna 150 mg Chemotherapy Tyrosine Kinase Inhibitor BCR-ABL Yes 2007 In Use
The use of NA indicates that the HCPCS code was Not Available. NA may mean that a) the HCPCS code has not yet been created (new drug), b) the drug is given as an oral drug or alternative route (only in specific instances are HCPCS assigned to these medications), or c) the HCPCS could not be found or is truly not available.